SCHEMBL6541793

SCHEMBL6541793

COc1ccc(-n2nnnc2C(F)(F)F)cc1CN1C[C@@H]2CN(C(=O)OCc3ccccc3)CCN2[C@H](C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.49

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 19/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6540986 1.00 TACR1 (0.49) TACR1
SCHEMBL7202264 1.00 TACR1 (0.49) TACR1
SCHEMBL7202258 1.00 TACR1 (0.49) TACR1
Hydrochloric Acid SCHEMBL6541523 0.94 TACR1 (0.51) TACR1
SCHEMBL6541529 0.93 TACR1 (0.57) TACR1
Hydrochloric Acid SCHEMBL6541521 0.92 TACR1 (0.57) TACR1
Hydrochloric Acid SCHEMBL6541557 0.91 TACR1 (0.51) TACR1
SCHEMBL6540743 0.91 TACR1 (0.56) TACR1
SCHEMBL7206455 0.91 TACR1 (0.51) TACR1
SCHEMBL7206460 0.91 TACR1 (0.51) TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6787543-B2 PREPARATION OF TACHYKININ ANTAGONISTS; SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-07 US disclosed
US-20030176430-A1 Benzhydryl derivatives ASTELLAS PHARMA INC. (JP) 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176430-A1 Benzhydryl derivatives BDKRB1, BDKRB2, TACR1 TACR1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.